LEADER 06337nam 2201777z- 450 001 9910557448703321 005 20231214133042.0 035 $a(CKB)5400000000043253 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68969 035 $a(EXLCZ)995400000000043253 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAntiviral Agents 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (386 p.) 311 $a3-03928-953-5 311 $a3-03928-954-3 330 $aAntiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents. 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 610 $aZika virus 610 $anucleoside analogues 610 $aantiviral agents 610 $aNS5 610 $aprodrugs 610 $aProTides 610 $aneural stem cells 610 $aRNA-dependent RNA polymerase 610 $acytomegalovirus 610 $alatent infection 610 $aTALEN 610 $aSurveyor nuclease mutation detection assay 610 $aie-1 gene 610 $aquantitative real-time PCR 610 $aEpstein-Barr virus 610 $aherpes viruses 610 $alytic gene expression 610 $aBurkitt lymphoma cells 610 $aclozapine 610 $aantipsychotic drug 610 $aantiviral drug 610 $aenteroviruses 610 $acoxsackievirus B4 610 $apersistent infection 610 $afluoxetine 610 $aresistance 610 $amutations 610 $aherpes B virus 610 $amacacine herpesvirus-1 610 $agenistein 610 $aflavonoids 610 $aacyclovir 610 $aganciclovir 610 $aPlantago asiatica 610 $aClerodendrum trichotomum 610 $aRSV 610 $atherapeutic effects 610 $aacteoside 610 $ahuman antimicrobial peptides 610 $aantiviral strategies 610 $adefensins 610 $acathelicidins 610 $ahepcidins 610 $atransferrins 610 $ainfluenza A virus 610 $abrevilin A 610 $aantiviral 610 $asesquiterpene lactone 610 $areplication 610 $aPRRSV 610 $apolyethylenimine 610 $aPEI 610 $avirion internalization 610 $aendocytosis 610 $aHIV 610 $apediatrics 610 $aEthiopia 610 $apre-treatment drug resistance 610 $acombination antiretroviral therapy (cART) 610 $adried plasma spots 610 $adried blood spots 610 $asphingolipids 610 $aglycosphingolipids 610 $aviruses 610 $alipid biosynthesis 610 $aflavivirus 610 $aJapanese encephalitis virus 610 $afurin inhibitor 610 $aprecursor membrane protein 610 $ameasles virus 610 $acentral nervous system 610 $atropism 610 $atreatments 610 $aporcine reproductive and respiratory syndrome virus 610 $aginsenoside Rg1 610 $aantiviral activity 610 $apro-inflammatory factor 610 $aNF-?B signaling pathway 610 $aacute/latent infection 610 $acongenital infection 610 $aantiviral agent 610 $atherapeutic strategies 610 $anucleic acid-based therapeutic approach 610 $aHCMV vaccine 610 $aadoptive cell therapy 610 $aRev response element 610 $achemical footprinting 610 $aSHAPE 610 $adrug discovery 610 $abranched peptides 610 $aherpesvirus 610 $aimmediate-early 610 $aIE1 610 $aIE2 610 $aribozyme 610 $aRNA interference 610 $aCRISPR/Cas 610 $asmall molecule 610 $aorthohantavirus 610 $aphenyl-benzotriazoles 610 $aC-FRA 610 $aPorcine circovirus type 2 610 $aepigallocatechin gallate 610 $aheparan sulfate 610 $aantiviral effect 610 $avirus attachment 610 $amicrovirin 610 $alectin 610 $ahuman immunodeficiency virus 610 $ahepatitis C virus 610 $aantiviral inhibitor 610 $anon-immunogenic 610 $aviral entry 610 $aprotein drugs 610 $aLUMS1 610 $aoleanane-type derivatives 610 $ainfluenza A virus (IAV) 610 $avirus entry inhibitors 610 $ahemagglutinin (HA) 615 7$aResearch & information: general 615 7$aBiology, life sciences 700 $aAdamson$b Catherine$4edt$01323411 702 $aAdamson$b Catherine$4oth 906 $aBOOK 912 $a9910557448703321 996 $aAntiviral Agents$93035519 997 $aUNINA